Le Lézard
Classified in: Health
Subject: ATY

Parker Waichman LLP Comments: DePuy Synthes Attune Knee Device Lawsuits Mounting



PORT WASHINGTON, N.Y., Oct. 5, 2017 /PRNewswire/ -- Parker Waichman LLP, a national law firm that has long been dedicated to protecting the rights of victims injured by allegedly defective drugs and medical devices, is commenting on DePuy Synthes Attune Knee Replacement problems. Reports submitted to the U.S. Food and Drug Administration (FDA) reveal an increased number of Attune failures are due, allegedly, to loosening?or debonding?at the cement border of the tibial baseplate. Premature failure typically takes place one-two years following implant, if not earlier. Such debonding of the tibial baseplate or tray leads to pain, swelling, inflammation, infection, instability, severe bone and/or muscle loss and damage, and other injuries, all necessitating more medical procedures or surgeries to remove and replace the device (revision surgery). Revision surgery is generally more painful, difficult, and costlier than initial surgery, especially if bone loss has developed. Revision surgery also generally involves longer, more complex therapy ad recovery.

"Parker Waichman represents many patients implanted with the Attune knee implant system who have subsequently suffered from serious and painful complications," says Keith Gitman, Managing Attorney. Parker Waichman is a nationwide law firm representing victims of the Attune knee system and continues to offer free legal reviews to individuals who allegedly suffered complications related to the Attune system.

Symptoms of Attune Knee implant failure may include instability and loosening, unusual swelling, persistent pain, warmth or heat in the knee, loss of or failure to bond of the system to bond to the bone, worn components, fracture, loss of osseointegration (loss of direct structural and functional connection between ordered, living bone and the surface of a load-carrying implant), and metal shedding debris.

Also, according to Mr. Gitman, "Whistleblowers are crucial in detecting and stopping fraud and are critical to ending illegal employer activities that may cause harm to patients." Mr. Gitman adds that, "Whistleblowers have long been crucial in helping to stop illegal activities by various entities, including medical device makers. Parker Waichman has also been involved in resolving cases involving fraud and have been equally important in maintaining whistleblower anonymity in these cases."

"This case opens up the potential for other cases of fraud to emerge," said Mr. Gitman.  "When medical device companies take part in illegal or unethical activities such as releasing potentially defective devices to the market, they are defrauding unsuspecting patients and physicians," added Mr. Gitman.

Filing a DePuy Synthes Attune Knee Replacement System Lawsuit

Parker Waichman LLP supports efforts to protect whistleblowers and offers free case evaluations to those individuals who believe their companies may be involved in wrongdoings.  Parker Waichman has also long represented clients in medical device injury lawsuits. If you or someone you know is interested in filing a DePuy Synthes Attune Knee Replacement System lawsuit, or if you believe that a device maker is committing fraudulent activities and would like to maintain your anonymity, contact Parker Waichman LLP at the firm's website at www.yourlawyer.com or call 1-800-LAW-INFO (1-800-529-4636).

SOURCE Parker Waichman LLP


These press releases may also interest you

at 21:30
HOUSTON, Oct. 19, 2017 /PRNewswire-USNewswire/ -- Former National Champion and College Football Hall of Famer Steve Spurrier can now add another win to his record as the 2018 American Heart Association (AHA) Paul "Bear" Bryant Lifetime Achievement...

at 21:00
TOKYO, Oct. 19, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Universal Cells, Inc. (CEO: Claudia Mitchell, "Universal Cells") today announced that Astellas Institute for Regenerative...

at 19:06
WASHINGTON, Oct. 19, 2017 /PRNewswire-USNewswire/ -- Cal Dooley, President and CEO of the American Chemistry Council (ACC) issued the following statement on the Reuters investigation into the International Agency for Cancer Research's (IARC)...

at 19:00
WASHINGTON, Oct. 19, 2017 /PRNewswire-USNewswire/ -- The latest results from an annual survey on dietary supplements reveals an all-time high for supplement usage among U.S. adults, with 76 percent reporting they consume dietary supplements, up five...

at 18:20
CORONA, Calif., Oct. 19, 2017 /PRNewswire/ -- Micro Lab Farms, the premier provider of fully automated and equipped repurposed shipping containers that provide a turnkey system for the growing of legal cannabis, announced that it has a variety of...

at 17:57
CUPERTINO, Calif., Oct. 19, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today reported that PERSIST, the Phase 3 clinical trial for POSIMIR® (SABER®-Bupivacaine), did not meet its primary efficacy endpoint of reduction in pain on movement...




News published on 5 october 2017 at 08:45 and distributed by: